Working… Menu

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02003144
Recruitment Status : Active, not recruiting
First Posted : December 6, 2013
Last Update Posted : February 17, 2021
Information provided by (Responsible Party):
Alexion Pharmaceuticals

Brief Summary:
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.

Condition or disease Intervention/treatment Phase
Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder Biological: eculizumab Phase 3

Detailed Description:
This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 119 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
Study Start Date : January 2015
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Arm Intervention/treatment
Experimental: Eculizumab
Eculizumab intravenous infusion every two weeks.
Biological: eculizumab
Other Name: Soliris

Primary Outcome Measures :
  1. Evaluate the long-term safety of eculizumab in patients with relapsing NMO. [ Time Frame: From first dose to study completion (maximum of 4 years). ]
    Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), change from baseline in vital signs, clinical laboratory tests, and suicide risk as assessed with Columbia-Suicide Rating Scale (C-SSRS)

Secondary Outcome Measures :
  1. Evaluate the long-term efficacy of eculizumab in patients with relapsing NMO [ Time Frame: From first dose to study completion (maximum of 4 years). ]
    Change from baseline in Annualized Relapsing Rate, disability, quality of life and neurologic function.

Other Outcome Measures:
  1. Describe the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab in patients with relapsing NMO [ Time Frame: From first dose to study completion (maximum of 4 years). ]
    Change in plasma PK of eculizumab and in free C5 activity (PD marker) before and after treatment with the study drug.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Patient completed the ECU-NMO-301 trial
  2. Patient has given written informed consent

Key Exclusion Criteria:

  1. Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related to trial drug
  2. Female patients who are pregnant, breastfeeding, or intend to conceive during the course of the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02003144

Show Show 69 study locations
Sponsors and Collaborators
Alexion Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alexion Pharmaceuticals Identifier: NCT02003144    
Other Study ID Numbers: ECU-NMO-302
2013-001151-12 ( EudraCT Number )
First Posted: December 6, 2013    Key Record Dates
Last Update Posted: February 17, 2021
Last Verified: February 2021
Keywords provided by Alexion Pharmaceuticals:
Long-term safety study
Extension trial
Neuromyelitis Optica Spectrum Disorder
Devic's disease
Transverse Myelitis
Optic Neuritis
CNS Autoimmune Disorders
Demyelinating Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromyelitis Optica
Myelitis, Transverse
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Optic Neuritis
Optic Nerve Diseases
Cranial Nerve Diseases
Demyelinating Diseases
Eye Diseases
Autoimmune Diseases
Immune System Diseases